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Spontaneous diabetes in the NOD mouse can be
prevented by nicotinamide or by an infant formula
diet in which the protein source is replaced with
casein hydrolysate (Pregestimil) or soy protein
(Prosobee). NOD mice maintained on the standard
diet (chow and water) and given cyclophosphamide
(Cy) at day 95 develop accelerated and synchronised
diabetes within 14 days. Here, we compared the
ability of oral nicotinamide or Prosobee, either given
alone or concurrently, from weaning, in preventing
diabetes in the Cy model. The resulting insulitis and
the expression of intra-islet inducible nitric oxide
synthase (iNOS) were examined at days 0, 4, 7, 11
and 14 following Cy administration. Intra-islet CD4
and CD8 cells and macrophages were also enumer-
ated at day 11. In mice given the standard diet and
injected with Cy at day 95 (group 5), diabetes
developed in 7/11 mice, 14 days later. Mice exposed
to oral nicotinamide (group 2), Prosobee (group 3) or
both (group 4), did not develop the disease during
this period and until a further 30 days (p 0.03). In
mice exposed to the standard diet and without Cy
treatment (group 1) the insulitis scores increased
slowly until day 11 and then declined slightly at day
14 whereas mice exposed to the same diet but given
Cy at day 95, showed a sharp decline at day 4
followed by a rapid increase between day 7-14.
However, in mice given either nicotinamide, Proso-
bee or both, the insulitis scores at most time-points
were generally lower than in Cy-treated animals on
the standard diet. In the latter group, CD4 and CD8
cells and macrophages were also higher at day 11
than all other 4 groups (CD4: p<0.05; CD8: p<0.05;
macrophages: p<0.0001). The number of iNOS
labelled cells increased progressively in mice on
the standard diet and given Cy and were signifi-
cantly higher at days 4, 7 and 11 than in the 3 dietary
groups. Thus, oral nicotinamide or Prosobee, either
alone or together, prevents Cy induced diabetes in
the NOD mouse. The protective diets suppress Cy-
induced intra-islet immune cell influx and iNOS
expression.
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INTRODUCTION
Several studies have described successful pre-
vention of insulin-dependent diabetes mellitus
(IDDM) in the NOD mouse. Some of these are
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currently being evaluated in human clinical
trials.11 Nicotinamide injected into adult NOD
mice over a protracted period or given orally
as drinking water from weaning prevents dia-
betes. [2’3] Complete protection is also achieved
with the complete infant formula, Pregestimil or
Prosobee in which the protein source is bovine
casein hydrolysate or soy protein, respectively,
when introduced from weaning.4’51 Epidemio-
logical reports suggest that ingestion of bovine
milk as the sole nutritional source by the human
newborn and during infancy may be an im-
portant etiological factor for the development of
IDDM. L6’71 These studies have been supported
by the recent demonstration of increased cellular
reactivity of blood mononuclear cells to bovine
fl-casein, lactoglobulin and humoral reactivity to
bovine serum albumin (BSA) and fl-lactoglobu-
lin, in newly-diagnosed diabetic subjects.8-11
However, the role of cow’s milk components
in the etiopathogenesis of human IDDM has
recently been questioned.Ll1-141 A large clinical
trial aimed at testing the efficacy of bovine
casein-hydrolysate based .infant formula in
preventing or delaying diabetes in high risk
[151 newborns is in progress.
Oral nicotinamide also delays the onset of
IDDM in diabetes-prone children. I16"171 A large
case-controlled clinical trial involving nicotina-
mide prophylaxis is in progress (the European
Nicotinamide Diabetes Intervention Trial (END-
IT)). However, the efficacy of nicotinamide in
preventing IDDM in high risk individuals and
with an assumed rapid progression to disease
may be low, as concluded from the recent
Deutsche Nicotinamide Intervention Study
(DENIS).181
Cyclophosphamide (Cy) when given to NOD
mice as a single injection promotes a rapid influx
of immune cells into the islets resulting in
accelerated and synchronised diabetes.9"21 In
this intensified model, nitric oxide (NO) may be
a key molecular mediator of beta cell destruction
since the heightened insulitis observed immedi-
ately preceding onset of diabetes is associated
with significant up-regulation of intra-islet
inducible nitric oxide synthase (iNOS). [20"21] Cy-
clophosphamide induced diabetes in the NOD
mouse may have some immunopathogenetic
similarities to the rapidly progressing form of
human IDDM. However, it is unclear if nicoti-
namide and the bovine casein-free infant for-
mula, previously shown to protect NOD mice
from spontaneous diabetes, are equally effective
in preventing diabetes in this accelerated model.
Here, we have, therefore, tested whether oral
nicotinamide or Prosobee, introduced to female
NOD mice from weaning, either alone or in
combination, would successfully prevent Cy-
induced diabetes. We have also examined some
of the likely immune and molecular mechanisms
which may underlie any protective effects
associated with such dietary treatments, includ-
ing their effects on insulitis, intra-islet immune
cell numbers and the expression of iNOS.
MATERIALS AND METHODS
Animals
A colony of NOD mice was established in
Auckland, New Zealand, under conventional
conditions, from three breeding pairs originally
obtained from the University of Ehime, Japan.
The rate of spontaneous diabetes among the
Auckland colony is 50% among females and
< 1% among males at 120 to 250 days. Diabetes
was defined as the presence of heavy glucosuria
on three consecutive days detected by Testape
(Eli Lilly, St Louis, IN, USA) and confirmed by
a hyperglycaemic value of > 12mM in blood
samples from the tail (Medisense blood glucose
meter).
Study Groups
Female NOD mice were generated from 10
breeding pairs through repeated breeding,
weaned at day 21 and allocated at random intoPREVENTION OF CYCLOPHOSPHAMIDE-INDUCED DIABETES 301
5 groups (23 mice per group). They were
exposed to various diets from day 21 until day
250 for group 1 mice and until day 140 for mice
from groups 2-5. The 5 experimental groups
were as follows:
Group 1: standard mouse chow (Diet 86, see
below) + drinking water.
Group 2: standard mouse chow+ 1% nicotina-
mide (New Zealand Tablet Manufactures) as
drinking water.
Group 3: Prosobee infant formula (Mead John-
son and Co, Evansville, IN, USA, see below for
composition) + drinking water.
Group 4: Prosobee infant formula + 1% nicoti-
namide as drinking water.
Group 5: standard mouse chow+drinking
water.
The composition of standard mouse chow
(Diet 86) and Prosobee infant formula was
identical to those used in our previous studies
[5] in the NOD mouse.
Chow (Diet 86)
Diet 86 contains wheat, barley, meat and bone
meal (derived from cows, pig and sheep and
includes offal) and is also supplemented with
minerals, trace elements and vitamins.
Prosobee Powder
Ingredients: Corn syrup solids, soy protein
isolate, corn oil, monoglyceride, minerals
(potassium citrate, calcium phosphate, calcium
chloride, magnesium chloride, calcium hydro-
xide, potassium bicarbonate, sodium citrate,
potassium hydroxide, ferrous sulphate, zinc
sulphate, manganese sulphate, cupric sulphate
and sodium iodide), vitamins (vitamin A,
palmitate, calciferol, DL-c-tocopherol acetate,
sodium ascorbate, folic acid, thiamine hydro-
chloride, riboflavin, niacinamide, pyridoxine
hydrochloride, cyanocobalamin, biotin, calcium
pantothenate and phytonadione), choline
bitartrate, L-methionine, taurine and ascorbyl
palmitate.
The principal constituents of Prosobee and
chow are given below:
Composition Prosobee Chow
Protein g 15.8 18.1
Fat g 27.9 5.6
Carbohydrate g 51.4 57
Minerals g 2.6
Water g 2.5 9.74
Choline mg 66 30
Calcium g 0.427 1.5
Salt g 1.03 1.36
Amino acids 6.0
Phosphorus g 0.310 0.84
Iodine tg 35 70
Linoleic acid g 8.0 1.27
Xanthophyll mg 8
Administration of Cyclophosphamide
and Tissue Collection
Cy was administered to NOD mice as described
recently.21 At day 95, all except 3 mice from
groups 2-5 were injected with Cy (Sigma, St.
Louis, USA) at a dose of 300mg/kg body weight
by the intra-peritoneal route.21 Group 1 mice
(controls) received diluent (sterile water). Fol-
lowing injection of Cy or diluent, 3 mice from
each group were sacrificed at days 0 (day 95 and
without Cy administration), 4, 7 and 11 and the
pancreas harvested (see below). The remaining
11 mice from each group were followed until
day 14 for development of diabetes. At day 14,
three mice from groups 1-4 and all 7 diabetic
mice from group 5 were killed and the pancreas
removed. The remaining non-diabetic mice from
the day 14 group were monitored for diabetes
for a further 30 days (groups 2-4) or until day
250 (group 1, spontaneous diabetes group).
At the various time-points described above
animals were killed by cervical dislocation and
almost the entire pancreas with a small portion302 S. REDDY et al.
of the adjacent spleen, was removed, embedded
in OCT and snap-frozen in isopentane cooled
in liquid nitrogen. Tissues were stored at -70C
until histochemical and immunohistochemical
analysis.
Primary Antibodies, Non-immune IgG
and Normal Sera
Polyclonal antibodies to mouse macrophage
iNOS (rabbit IgG fraction, I mg/ml) were pre-
pared by Dr. C. Nathan, Cornell University
Medical College, New York, USA and supplied
by Upstate Biotechnology, New York, USA. The
monospecificity of this antibody for mouse iNOS
has been reported previously, and it has been
employed for immunohistochemical labelling
of the enzyme in lipopolysaccharide (LPS) and
interferon--y (IFN-/) activated mouse peritoneal
macrophages. I221 This antibody has subse-
quently been employed by the same authors
for immunolocalization of iNOS in pancreatic
sections of the BB rat and by us and other
investigators in the NOD mouse. [20’23"24]
Dr. H. Georgiou of the Walter and Eliza Hall
Institute, Melbourne, Australia supplied rat
monoclonal antibodies to mouse macrophages
(MAC-l, clone M/170), CD4 (clone GK 1.5) and
CD8 (clone 53-6.72) in the form of culture
supernatants. The same monoclonal antibodies
have been previously used for immunohisto-
chemical staining of sections of pancreas from
the NOD mouse in this laboratory. 25’261
In the immunohistochemical procedure, all
primary antisera were titrated to give maximal
immunohistochemical reactivity. Normal sera
from the goat, sheep, donkey, rabbit, guinea
pig, rat and mouse were available in this
laboratory.
Histochemical Staining and Evaluation
of Insulitis
Serial frozen sections (8 tm) were prepared from
different levels of the pancreas, thaw-mounted
on glass slides and fixed in cold acetone for
10min and stored at -20C until required.
Sections from each level were stained by
Haematoxylin and Eosin (H and E) and the
islets graded for the severity of insulitis from
a scale of 0-4 as reported previously.2 By
this method, islets devoid of any mononuclear
cells=0, minimum focal islet infiltrate=14-;
peri-islet infiltrate of <25% of islet circum-
ference-- 2 4-; peri-islet infiltration and < 50%
intra-islet infiltrate=34-; intra-islet infiltration
>50% of islet area=4+. All slides were
coded and at least 10 separate islets from differ-
ent levels of the pancreas of each animal were
scored. The insulitis score (%) for each study
group was calculated as follows:
Sum of (1 x number of islets with 1+,
2 x number of islets with 2 4-, 3 x number of
islets with 3 +, 4 x number of islets with 4 4-)
divided by 4 x total number of islets scored. The
ratio obtained was expressed as a percentage.
The insulitis score (%) for each study group was
expressed as the mean 4-SEM.
Immunolabelling and Enumeration of CD4
and CD8 Cells and Macrophages
Pancreatic sections at day 11 belonging to the
5 groups were immunolabelled by the immu-
noperoxidase technique for CD4 and CD8 cells
and macrophages as described previously, with
minor modifications.3"261 During the immuno-
histochemical procedure (described below) sec-
tions were washed in excess phosphate-buffered
saline (PBS), pH 7.5, before addition of each
immunological reagent. Prior to commencement
of immunohistochemical labelling, sections were
routinely re-fixed briefly in cold acetone and
equilibrated in PBS.
Following blocking with 5% normal rabbit
serum and 1% rabbit anti-mouse IgG (Sigma, St.
Louis, MO, USA), monoclonal antibodies to CD4
and CD8 cells and macrophages were applied
to serial sections of pancreas and incubated
for 2.5h at 37C. After washing, sections werePREVENTION OF CYCLOPHOSPHAMIDE-INDUCED DIABETES 303
incubated with rabbit anti-rat IgG-biotin (1:100,
Vector, Burlingame, CA, USA) for I h at 37C.
Endogenous peroxidase activity was blocked
with 0.5% H202 in methanol. Sections were
washed and reacted with Vectastain Elite ABC-
peroxidase reagent (Vector) for l h at 37C.
Sections were exposed to diaminobenzidine
hydrochloride in the presence of H202 to reveal
the presence of immunoreactive cells and
counterstained with haematoxylin. They were
dehydrated with graded series of alcohol, cleared
in xylene and viewed with a Leica microscope
attached to a video monitor (see below). Macro-
phage immunolabelling was also carried out by
immunofluorescence as described previously.
24]
Following incubation with Mac-1 antibody,
sections were reacted with rabbit anti-rat
IgG-biotin followed by streptavidin-Texas Red
(Jackson Immunoresearch Laboratories, West
Grove, PA, USA). Sections were prepared for
microscopic examination.
The number of immunoperoxidase-stained
CD4 cells, CD8 cells or macrophages present
within the islets and immediately outside but
in close apposition to the islet boundary were
either counted microscopically or following dis-
play on a monitor. [2’26] At least 10 islets from
each animal were analysed. Results were ex-
pressed as the mean number of immune cells per
islet for each group 4- SEM.
Immunolabelling and Enumeration
of iNOS
Immunohistochemical labelling of iNOS was
carried out as described recently, with minor
modifications.I2’24 Following blocking with
normal sheep serum, sections were incubated
with anti-iNOS (1:200) for 16h at room
temperature followed by incubation with goat
anti-rabbit IgG-biotin (1:200, Jackson Immuno-
research Laboratories) for I h at 37C. Sections
were finally incubated with streptavidin-Texas
Red (1:200, Jackson Immunoresearch Labora-
tories) for I h at 37C, washed and mounted with
glycerol:PBS before microscopic examination
and photomicrography.
Adjacent sections from day 11 pancreas were
also immunolabelled for macrophages as de-
scribed above. Macrophage-positive cells were
visualized using streptavidin-Texas Red instead
of streptavidin-peroxidase.
The number of intra-islet iNOS positive cells
were enumerated at days 0, 4, 7 and 11 (days 0, 4
and 7 for group 5) either by direct microscopic
visualization or following photography and
were expressed as the mean 4- SEM per islet.
Light Microscopy and Photography
Sections were examined with a Leica light or
Olympus UV-visible microscope equipped with
excitation filters for Texas Red (568nm) and
fluorescein (488 nm) and mercury and halogen
lamps. At least 10 islets from each pancreas and
the entire exocrine region on each slide were
analyzed.
Appropriate fields from light immunofluo-
rescent and immunoperoxidase stained sections
agd following H and E staining were photo-
graphed with a Kodak Ektachrome 200 ASA film
and the images scanned to a photo compact disk.
Immunohistochemical Controls
In the immunohistochemical procedure for
iNOS, the primary antibody was replaced with
buffer, normal rabbit IgG or normal sera from
a rabbit, mouse, rat or guinea pig at equivalent
dilutions. In addition, primary and secondary
steps were omitted.
Statistical Analysis
A Chi square test was used to investigate
differences in diabetes rate among the groups.
An exact probability was calculated because
of the small expected numbers. An analysis of
variance was used to investigate differences in304 S. REDDY et al.
insulitis scores in the 5 groups and the differ-
ences over time. An arc sine transformation was
used to allow for the distribution of the insulitis
scores. The level of significance was found using
Scheffes test. Intra-islet CD4 and CD8 cells and
macrophages were analysed separately by
analysis of variance. Levels of significance were
determined by Scheffes test. For intra-islet iNOS
cell numbers, a logistic regression was used
to investigate whether there was a difference
between the groups and a change over time.
A Chi square test was employed to determine
significance between time and group.
RESULTS
Incidence of Diabetes
The incidence of Cy-induced diabetes in the 5
experimental groups is shown in the following
table:
Cy-induced
Groups diabetes
1: Standard diet and without Cy
2. Standard diet and nicotinamide + Cy
3. Prosobee + Cy
4. Prosobee and nicotinamide + Cy
5. Standard diet + Cy
0/11
0/11
0/11
0/11
7/11
In group 5, Cy administration resulted in dia-
betes in 7/11 mice (63%) 14 days later. During
the same period, none of the 11 mice from
groups 1-4 developed the disease (p=0.03,
Chi square test). In groups 2-4, none of the
8 remaining mice developed diabetes when
followed for 45 days after Cy administration.
In mice which did not receive Cy (group 1, chow
and water, n 8) spontaneous diabetes develop-
ed in 4/8 mice (1 at day 128, 2 at day 142 and 1
at day 182). There were no differences in body
weights between the various diet- and Cy-
treated groups.
Severity of Insulitis
Figure 1 shows representative islets from the 5
groups following H and E staining of pancreatic
sections. In group 1, significant infiltration
was seen from day 0 to day 14 (Fig. la, b). In
group 2 (nicotinamide treated), majority of the
islets were either insulitis free or had peri-islet
infiltration (Fig. 1 c-h). A similar pattern was
also seen in group 3 (Prosobee-fed) until day 7
(Fig. 1 i, j). However, the severity of insulitis
became more pronounced by days 11 and 14
(Fig. I k, 1). In group 4 (Prosobee + nicotinamide),
many islets were well preserved throughout
the 14 day study period, although some
were heavily infiltrated (Fig. 1 m-o). In group
5 (Cy treated, chow and water), islets became
heavily infiltrated from day 7 onwards (Fig. 1
p-r).
The mean 4-SEM insulitis scores (%) in the
various experimental groups at days 0, 4, 7, 11
and 14 are shown in Figure 2. For group 5, the
insulitis score at day 14 represents the mean
of 3 diabetic mice whereas for groups 1-4, the
means are from non-diabetic mice (3 mice per
group).
In mice exposed to the standard diet and
given Cy, the insulitis score declined rapidly
at day 4 but increased sharply by day 7 and
remained elevated at days 11 and 14 (Fig. 2).
Although the insulitis scores increased at days
11-14, diabetes was not observed for an addi-
tional month. The reasons for the continued
protection are unclear but may be due to a
switch towards protective cytokines in the islet
infiltrate. In all 5 groups, there was a significant
stage effect (F5.71 =6.47; p=0.0001) with the
insulitis scores generally increasing over time.
There were differences in the level of insulitis
in the 5 groups as a whole (F4.754; p 0.001).
A multiple comparison of the means using
Scheffes test showed that the insulitis scores
were significantly higher in group 5 than in
groups 2-4 (p =0.05). They were also higher in
group 1 than in groups 2-4 (p =0.05).PREVENTION OF CYCLOPHOSPHAMIDE-INDUCED DIABETES 305
FIGURE Photomicrographs of pancreatic sections stained by H and E, showing representative islets with insulitis from
groups 1-5. a, b: Group 1, (a): day 4 and (b): day 7. c-h: Group 2, (c,d): day 0; (e,f): day 4; (g): day 7; (h): day 14. Note well-
preserved islets at most stages, i- 1: Group 3, (i): day 0; (j): day 7; (k): day 11; (1): day 14. Note advanced insulitis at days 11 and
14. m-o: Group 4, (m): day 0; (n): day 7; (o): day 11. Note insulitis-free islets at days 0 and 7 but advanced insulitis at day 11.
p-r: Group 5, (p): day 0; (q): day 7; (r): day 11. Note advanced insulitis from day 7. (a-f) and (n-r): x 200; (g-m): x 100. (See
Color Plate II).
Intra-islet CD4 and CD8 T Cells
and Macrophages
In all 5 experimental groups, the intra-islet
distribution of CD4 and CD8 cells and macro-
phages at day 11 was variable. This is shown in
Figure 3.
Figure 4 shows the mean + SEM number of
CD4 and CD8 cells and macrophages per islet at
day 11 in the 5 groups. All 3 cell-types showed
differences between the groups (macrophages:
F4.169 19.44, p < 0.0001; CD4: F4,170 4.22,
p 0.003; CD8: F4.169-- 13.89, p < 0.0001). Intra-
islet macrophage numbers were significantly
higher in group 5 than in the other 4 groups
(p < 0.05). They were also lower in the control
group (group 1) than in groups 2 and 4306 S. REDDY et al.
Group 1
Group 2
Group 3
Group 4
Group
Days after cyclophosphamide administration
FIGURE 2 The mean insulitis scores (% 4- SEM) at days 0,
4, 7, 11 and 14 in cyclophosphamide-treated (groups 2-5) or
diluent-treated (group 1) mice. Insulitis scores were obtained
from 3 mice at each time-point. For group 5, the insulitis at
day 14 represents the mean from 3 diabetic mice whereas for
groups 1-4, the scores are from 3 non-diabetic mice per
group.
(p < 0.05). No significant differences in macro-
phage numbers were observed between the 3
dietary groups (groups 2-4).
Intra-islet CD4 cells were significantly higher
in group 5 than in groups 3 and 4 (p < 0.05),
whereas intra-islet CD8 cells were significant-
ly higher in group 5 than in groups 1-4
(p < 0.05).
Intra-islet iNOS Expression
The distribution of intra-islet iNOS immuno-
reactive cells in the various study groups is
shown in Figure 5. In group 1, expression of the
enzyme was observed rarely and only in a few
infiltrated islets (Fig. 5 a,b). Weak intra-islet
expression for the enzyme was first observed
at day 4 only in group 5 mice and became
more numerous and intense at days 7 and 11.
In groups 2-4, iNOS was expressed in a small
number of intra-islet cells at days 7 and 11. In
groups 1-4, several islets showed an absence or
only minimal expression of iNOS despite sig-
nificant macrophage infiltration (Fig. 5).
The mean 4-SEM number of iNOS expressing
cells per islet in the various experimental groups
were analysed at days 0, 4, 7 and 11 and are
shown in Figure 6. In group 5, a large proportion
of islets at day 11 showed extremely intense
staining for the enzyme, and thus did not permit
reliable enumeration. Therefore, iNOS positive
cells in this group were enumerated at days 0, 4,
and 7 only. As seen in Figure 6, iNOS expressing
cells were first observed among group 5 mice at
day 4, which then increased sharply at days 7
and 11. The enzyme was observed in only a few
islet cells in mice from group 1.
The mean number of intra-islet iNOS ex-
pressing cells was higher in group 5 at days 4,
7 and 11 (p 0.001, Chi square) compared with
comparable time-points from groups 1-4. The
number of iNOS expressing cells at day 7 was
not significantly different between groups 2-4.
At day 11, group 2 mice had slightly higher
iNOS expressing cells compared with groups 3
and 4.FIGURE 3 Representative photomicrographs of pancreatic islets from day 11 stained by immunoperoxidase for CD4 and CD8
cells and macrophages, respectively, in groups I (a- c), 2 (d f), 3 g- i), 4 (j- 1) and 5 (m- o). In groups 1, 2, 3 and 5, the same islets
are shown from 3 serial sections whereas in group 4, (j) and (1) show the same islets in adjacent sections. (a- i): x 200; (j- o): x 100.
(See Color Plate III).
350 . 300
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FIGURE 4 The mean 4- SEM number of CD4 cells, CD8 cells and macrophages per islet at day 11 in groups 1- 5.308 S. REDDY et al.
FIGURE 5 Immunofluorescence photomicrographs showing pancreatic islets at day 11 from groups 1- 5, immunolabelled for
iNOS and macrophages.
a,b: Group 1. (a) and (b): two serial sections showing the same islet immunolabelled for iNOS (a) and macrophages (b).
Arrowheads point to only a few iNOS cells (a) and to numerous macrophages (b).
c-e: Group 2: (c): iNOS (arrowheads). (d) and (e) are two serial sections showing the same islet immunolabelled for iNOS (d)
and macrophages (e). Arrowheads point to numerous macrophages distributed as a peri-islet band while arrowheads in (d)
point to the corresponding area which is negative for iNOS.
f-h: Group 3: (f): iNOS (arrowhead). (g) and (h): same islet from 2 serial sections immunolabelled for iNOS (g) and
macrophages (h). Arrowhead in (h) points to numerous intra-islet macrophages while arrowheads in (g) point to the
corresponding area which is negative for iNOS. Only a few iNOS positive cells are visible (g) (arrow).
i-k: Group 4: (i): iNOS (arrowheads). (j) and (k) show the same islet from 2 serial sections immunolabelled for iNOS (j) and
macrophages (k). Arrowheads in (k) point to numerous intra-islet macrophages while arrowheads in (j) point to the
corresponding area, which is negative for iNOS.
1-o: Group 5: (l-n) show islets strongly immunolabelled for iNOS. (1) shows 2 adjacent islets with iNOS immunolabelling in
selective intra-islet cells. (m) and (n): islets with predominant and intense iNOS immunolabelling. (o) is a serial section of (n)
showing the same is let stained for macrophages. (a-l): x 200; (m-o): x 400. (See Color Plate IV).
Control Results for Immunohistochemistry
There was an absence of immunolabelling for
iNOS when the primary immune IgG was
replaced by normal rabbit serum or normal
rabbit IgG at equivalent dilution or by PBS.
Labelling was also absent when anti-iNOS and
biotinylated goat anti-rabbit IgG were omitted,
or when the secondary step was replaced with
biotinylated antibodies against rat IgG. In the
immunohistochemical procedure for CD4 and
CD8 cells and macrophages there was anPREVENTION OF CYCLOPHOSPHAMIDE-INDUCED DIABETES 309
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FIGURE 6 Mean number 4- SEM of iNOS expressing cells per islet at days 0, 4, 7 and 11 (groups 1-4) and days 0, 4 and
7 (group 5). The mean number of iNOS positive cells per islet at day 11 in group 5 far exceeded other time-points (see
Fig. 6 (m-o)).
absence of labelling when the primary antibodies
were replaced with normal rat serum (diluted
1:50 and 1:100). Immune cell staining was
not observed when the secondary step was
excluded.
DISCUSSION
In this study we have employed the Cy model of
accelerated diabetes in the NOD mouse to test
the efficacy of oral nicotinamide and Prosobee,
either given alone, or in combination, in pre-
venting diabetes. The three dietary treatments
were shown to successfully prevent diabetes
in the Cy model. The same dietary approaches
have been shown previously to produce long-
lasting protection from spontaneous diabetes in
the NOD mouse.
[5] In the present study, we also
examined some of the likely immune mechan-
isms underlying dietary protection in the Cy
model.
NOD mice maintained on the standard diet
(chow and water) and given a single injection
of Cy at day 95 developed diabetes at a rate of
63% in a synchronous manner 14 days later.
However, prior exposure to oral nicotinamide or
Prosobee, either alone or together from weaning,
resulted in complete protection from the more
intensified form of diabetes induced by Cy.
Other dietary ploys, such as Pregestimil or
Nutramigen, a bovine casein-hydrolysate based
infant formula, may also be equally protective in
mice given Cy, since the same formulae prevent
[4,5,27,28] spontaneous disease in the NOD mouse.
In the NOD mouse, islet cell directed auto-
antibodies and mononuclear cell infiltration
of pancreatic islets are detectable after wean-
ing.
[29’301 Insulitis increases progressively soon
after and by day 90-100 many islets have severe
insulitis.[3’26"3] Cy given to NOD mice main-
tained on the standard diet induces a massive
and progressive infiltration of immune cells
within the islets, as shown in this study and
[201 previously. However, as shown here and also
in a previous study, administration of Cy to
NOD mice results in an initial abrupt decline in
the severity of insulitis followed by a sharp and
sustained increase until diabetes supervenes.
31]
The reasons for the initial rapid decline in
insulitis after Cy treatment are unclear. Mice
fed nicotinamide or Prosobee or in combination310 S. REDDY et al.
showed significantly less insulitis and in parti-
cular, during the first 7 days after Cy treatment.
Exposure ofNOD mice to oral nicotinamide and
maintained on the standard chow diet showed
less insulitis at day 90 than in control mice.TM
However, the same degree of suppression was
not observed when given Prosobee despite
protection from disease.5 The marked suppres-
sion of insulitis achieved in the present study
with Prosobee plus nicotinamide is comparable
to that achieved by the combined diet during
spontaneous diabetes.51 It is possible that the
combination diet may contribute significantly to
beta cell resistance and/or immune protection.
The persistence of insulitis in diabetes-free
mice observed in this study following dietary
manipulation or by other interventions, such as
oral insulin, suggests that a Th2-type cytokine
milieu may predominate in the infiltrated
islet. [32’331 This may also be true in the BB rat.
[341
Following Cy administration to female NOD
mice, insulitis reaches its peak immediately
before diabetes, at day 11 (20; this study). Thus,
in this study, pancreatic tissues were analysed at
day 11 to determine whether numerical differ-
ences in intra-islet CD4 and CD8 T-cell and
macrophage phenotypes in the five experimen-
tal groups may contribute to protection or
promotion of disease. In the three dietary
groups, and in control mice not receiving Cy,
the number of the three cell-types within the
islets were significantly lower than in Cy-treated
mice on the standard diet. This reduction closely
mirrored the suppression of insulitis seen in
the various groups. Thus, dietary prophylaxis
may attenuate beta cell directed immune reacti-
vity and preserve sufficient beta cell mass to
maintain normoglycaemia. The protective diets,
particularly, the soy protein may also be modu-
lating the gut associated lymphoid system in
favour of a Th2 cytokine bias. I35
Cy given to NOD mice on the standard diet
results in a marked up-regulation of iNOS
in intra-islet macrophages, a major source of
the enzyme.
[2’211 The marked inhibition of
intra-islet iNOS labelling in mice exposed to
the three diabetes-preventing diets is note-
worthy. Thus, production of NO, following
transcription and translation of iNOS, may be a
critical effector molecule mediating beta cell
destruction in this model. The marked expres-
sion of iNOS is also seen in the later stages of
Cy-induced diabetes.2 However, in the present
study, all three groups exposed to the anti-
diabetogenic diets showed only a modest in-
crease in intra-islet iNOS and at the later stages
of Cy administration and despite significant
macrophage infiltration in several islets.
Therefore, nicotinamide and Prosobee may
down-regulate iNOS expression and thus limit
intra-islet NO production. Macrophages are
thought to mediate beta cell destruction through
NO production. Exposure of rat islets to acti-
vated macrophages in culture causes beta cell
lysis which is prevented by co-incubation with
nicotinamide.36’371 A similar effect is seen
following exposure of rat islets to nitrogen
donors such as sodium nitroprusside.38 Inter-
leukin-lfl has been shown to promote gene
expression of iNOS through activation of the
transcription factor NFKB in rat islets or rat
insulinoma cell line.
[391 Purified rat islets when
co-incubated with nicotinamide inhibits inter-
leukin-lfl-induced NO production in isolated rat
islets and protects beta cells from destruction.41
High nicotinamide concentrations, i.e., 10mM,
or more reduce IL-l-induced NO formation
from isolated islets and from RINm5F cells.
[411
Under these conditions, nicotinamide may have
post-transcriptionally regulated iNOS expres-
sion. However, at 50mM, nicotinamide also
[401 reduced iNOS gene expression. Nicotinamide
and Prosobee may, therefore, inhibit iNOS gene
expression and its translation in vivo. A similar
inhibitory effect on iNOS gene expression is seen
in lipopolysaccharide-activated macrophages
following linomide therapy in MRL/Mp-lpr/lpr
mice.
[42] Interestingly, linomide also prevents
diabetes in the NOD mouse. [43] Administration
of anti-IL-lfl protects NOD mice fromPREVENTION OF CYCLOPHOSPHAMIDE-INDUCED DIABETES 311
Cy-induced diabetes. I441 Whether the protective
diets employed in this study also down-regulate
intra-islet interleukin-fl expression are unclear.
Nicotinamide may also directly protect beta cells
from immune attack by inhibiting beta cell poly
(ADP) ribose polymerase (PARP) or promote
beta cell regeneration.
[45-491
In conclusion, this study shows that nicotina-
mide or Prosobee, either given singly or in
combination, successfully prevent the more
aggressive form of diabetes in the NOD mouse
induced by Cy. The three dietary treatments
suppress insulitis and down-regulate the ex-
pression of intra-islet iNOS. These anti-diabeto-
genic effects may result in beta cell resistance
and attenuation of beta cell directed cytotoxic
processes. The present findings in the Cy model
provide scientific rationale for further research
aimed at implementing non-invasive dietary
interventions for the prevention of IDDM in
humans.
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